See more : Lupin Limited (LUPIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Awakn Life Sciences Corp. (AWKNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Awakn Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yatra Online, Inc. (YTRA) Income Statement Analysis – Financial Results
- Nomad Foods Limited (NOMD) Income Statement Analysis – Financial Results
- Iyogin Holdings,Inc. (5830.T) Income Statement Analysis – Financial Results
- Kallebäck Property Invest AB (publ) (KAPIAB.ST) Income Statement Analysis – Financial Results
- Orbite Technologies Inc. (EORBF) Income Statement Analysis – Financial Results
Awakn Life Sciences Corp. (AWKNF)
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 87.37K | 1.50M | 236.04K | 0.00 |
| Cost of Revenue | 18.30K | 603.53K | 512.87K | 0.00 |
| Gross Profit | 69.08K | 891.81K | -276.83K | 0.00 |
| Gross Profit Ratio | 79.06% | 59.64% | -117.28% | 0.00% |
| Research & Development | 827.82K | 1.57M | 3.31M | 0.00 |
| General & Administrative | 2.73M | 4.06M | 4.40M | 666.73K |
| Selling & Marketing | 439.59K | 1.40M | 1.63M | 103.18K |
| SG&A | 3.17M | 8.51M | 6.54M | 823.07K |
| Other Expenses | 0.00 | -2.37K | 10.35K | 0.00 |
| Operating Expenses | 87.37K | 10.08M | 9.85M | 1.46M |
| Cost & Expenses | 4.00M | 10.69M | 10.03M | 1.46M |
| Interest Income | 87.67K | 305.79K | 0.00 | 13.10K |
| Interest Expense | 0.00 | 266.52K | 205.43K | 0.00 |
| Depreciation & Amortization | 18.30K | 14.41K | 181.41K | 84.00 |
| EBITDA | -3.91M | -5.26M | -16.08M | -840.22K |
| EBITDA Ratio | -4,473.00% | -574.33% | -4,072.48% | 0.00% |
| Operating Income | -3.93M | -9.19M | -9.79M | -840.30K |
| Operating Income Ratio | -4,493.94% | -614.69% | -4,149.34% | 0.00% |
| Total Other Income/Expenses | 255.42K | 306.31K | -6.86M | -652.12K |
| Income Before Tax | -3.67M | -9.65M | -16.47M | -1.48M |
| Income Before Tax Ratio | -4,201.61% | -645.44% | -6,978.45% | 0.00% |
| Income Tax Expense | 0.00 | -509.02K | -525.87K | -215.30K |
| Net Income | -5.10M | -9.14M | -15.95M | -1.26M |
| Net Income Ratio | -5,840.14% | -611.40% | -6,755.65% | 0.00% |
| EPS | -0.09 | -0.36 | -0.73 | -0.10 |
| EPS Diluted | -0.13 | -0.36 | -0.73 | -0.10 |
| Weighted Avg Shares Out | 39.68M | 25.20M | 21.96M | 12.63M |
| Weighted Avg Shares Out (Dil) | 29.07M | 25.20M | 21.96M | 12.63M |
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces the opening of four...
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a new research partnership...
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - October 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, with a near-term...
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on...
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to provide an update on the progress of its...
Graft Polymer CEO thrilled Awakn Life Sciences partnership progress
Graft Polymer (UK) PLC (LSE:GPL) has reported significant advances in its collaboration with Awakn Life Sciences Corp aimed at developing new therapeutics for trauma-related mental health disorders, including post-traumatic stress disorder (PTSD). Awakn has successfully identified two aminoindane chemical series as lead...
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on...
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Toronto, Ontario--(Newsfile Corp. - July 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on...
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on...
Graft Polymer inks drug delivery collaboration with Awakn Life Sciences
Graft Polymer (UK) PLC has finalised its operational review, resulting in a commercial collaboration with Awakn Life Sciences Corp. This partnership aims to advance Awakn's novel aminoindane new chemical entity (NCE) series, which has shown promise in treating post-traumatic stress...
Source: https://incomestatements.info
Category: Stock Reports